Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Rhea-AI Summary

Rezolute (Nasdaq: RZLT), a late-stage biopharmaceutical company focused on developing novel therapies for rare diseases, has announced its participation in the BTIG Virtual Biotechnology Conference. The company's CEO and Founder, Nevan Charles Elam, will engage in a fireside chat on August 5, 2024, at 12:00 p.m. ET.

The Rezolute management team will also be available for one-on-one investor meetings throughout the conference. Interested investors are encouraged to contact their BTIG representative to schedule a meeting. This event provides an opportunity for Rezolute to showcase its progress in developing transformative therapies and engage with potential investors.

REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced that Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute, will participate in a fireside chat during the BTIG Virtual Biotechnology Conference on Monday, August 5, 2024, at 12:00 p.m. ET.

Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their BTIG representative.

About Rezolute, Inc.

Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, RZ358, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital hyperinsulinism (cHI) and tumor hyperinsulinism (tHI).

Contacts:

Rezolute, Inc.
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717

LHA Investor Relations
Tirth T. Patel
tpatel@lhai.com
212-201-6614

FAQ

When is Rezolute (RZLT) participating in the BTIG Virtual Biotechnology Conference?

Rezolute (RZLT) is participating in the BTIG Virtual Biotechnology Conference on Monday, August 5, 2024. The company's CEO, Nevan Charles Elam, will be part of a fireside chat at 12:00 p.m. ET.

Who will represent Rezolute (RZLT) at the BTIG Virtual Biotechnology Conference?

Nevan Charles Elam, the Chief Executive Officer and Founder of Rezolute (RZLT), will represent the company at the BTIG Virtual Biotechnology Conference, participating in a fireside chat.

How can investors meet with Rezolute (RZLT) management during the BTIG conference?

Investors interested in meeting with Rezolute (RZLT) management during the BTIG Virtual Biotechnology Conference should contact their BTIG representative to schedule a one-on-one meeting.

What is the focus of Rezolute (RZLT) as a biopharmaceutical company?

Rezolute (RZLT) is a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases.